Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm

Adenomas Clinical Trial

Official title:

A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02654418
• Other study ID #: CB-17-04/01
• Status: Completed
• Phase: N/A
• First received: January 7, 2016
• Last updated: September 1, 2017
• Start date: February 2016
• Est. completion date: July 2017

Study information

• Verified date: February 2017
• Source: Cosmo Technologies Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SIC 8000 is indicated for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare.

Description:

SIC 8000 is indicated for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers or other gastrointestinal mucosal lesions, prior to excision with a snare.

The current trial will focus on only colonic polyps ≥20 mm removed by snare EMR technique.

Patients with lesions not suitable for EMR because of features strongly suggestive of sub-mucosal invasion will not be included.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Est. completion date: July 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Presence of treatment naïve, laterally spreading sessile, flat polyps or adenomas of the colon equal to or greater than 20 mm in largest dimension, assessed by the investigator to be suitable for EMR.

2. The base of the lesion should measure at least 20mm in at least one dimension.

3. A photograph demonstrating the lesion size =20 mm against a stiff Boston Scientific Captivator snare of 20 mm must be recorded for each patient prior to randomization.

4. ASA status: limited anesthesiology risk, with ASA score 1, 2 or 3.

5. Contraception: women of childbearing potential must use at least one reliable method of contraception or be abstinent. Women of non-child-bearing potential or in post-menopausal status must have been in that status for at least 1 year. For all women of child-bearing potential, serum pregnancy test result must be negative at screening.

6. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.

7. Informed consent: signed written informed consent must be completed before inclusion in the study.

Exclusion Criteria:

1. Age: Subjects under 18 years old are excluded

2. Consent: Subjects who refuse or who are unable to consent, vulnerable subjects are excluded.

3. Pregnancy: Pregnant or breastfeeding women

4. ASA status: High anesthetic risk (ASA score > 3)

5. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study

6. Study participation: Subjects currently enrolled in any other clinical study or previous enrollment in a clinical study in the last 30 days

7. Subjects with Lesions less than 20 mm in largest dimension

8. Subjects with Lesions involving the muscularis propria (T2 lesions) on other staging modalities such as endoscopic ultrasonography (EUS)

9. Subjects with ulcerated depressed lesions (Paris type III) or biopsy proven invasive carcinoma

10. Presence of other malignant disease locally advanced or with metastasis

11. Presence of other lesions of the digestive tract as active Inflammatory colonic conditions (inflammatory bowel disease , e.g ulcerative colitis, Crohn's disease)

12. Endoscopic appearance of invasive malignancy

13. Previous treatment of the lesion (radiotherapy, endoscopy, surgery, chemotherapy) is exclusionary. Previous cold biopsy of the target lesion is not an exclusion criteria.

14. Previous partial resection or attempted resection of the target lesion is exclusionary.

15. Allergy: ascertained or presumptive hypersensitivity to study products; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study.

16. known or suspected gastrointestinal obstruction or perforation, toxic megacolon, active diverticulitis.

17. inflammatory bowel disease e.g ulcerative colitis or Crohn's 's disease

18. Hemostasis disorders (eg Von Willebran disease, haemophilia or factor V Leiden thrombophilia), known clotting disorder (INR>1.5 that cannot be corrected).

19. Other medical condition that in the investigator's opinion would make the administration of the study IMD or procedures hazardous to the subject.

20. Medical treatments (i.e.: radiotherapy, surgical endoscopic treatments) before the intervention.

Related Conditions & MeSH terms

• Adenoma
• Adenomas

Intervention

Procedure:
• Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)

Locations

Country	Name	City	State
Italy	Humanitas Research Hospital & Humanitas University	Milan
United Kingdom	Queen Alexandra Hospital	Portsmouth
United States	Indiana University Hospital	Indianapolis	Indiana
United States	Mayo Clinic	Jacksonville	Florida
United States	Kansas City VA Hospital	Kansas City	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Cosmo Technologies Ltd

Countries where clinical trial is conducted

United States,  Italy,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sydney Resection Quotient (size of polyp in mm divided by number of resection pieces).		At V2 day of Endoscopic Mucosal resection of polyp (Day 1)
Primary	Proportion of subjects with en bloc resection of all endoscopically visible lesion		At V2 day of endoscopy (Day 1)
Secondary	Effectiveness compared to the reference comparator in terms of injected volume to provide initial polyp lift		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Injected volume required to complete the procedure		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Number of re-injections required to complete the procedure		At V2 day of Endoscopic Mucosal Resection (Day 1)
Secondary	Number of resection pieces		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Ease of use rated on 5-point scale		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Time to resect the lesion completely		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Number of single session complete removal of lesions		At V2 day of Endoscopic Mucosal Reseaction (day 1)
Secondary	Need for additional treatment modalities (eg coagulation, ablation, avulsion)		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Pathology negative report for lateral and/or deep margins		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Number of deep resections containing muscularis propria		At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Histologically positive or negative Free margin confirmed in en-bloc resections	Histologist will assess if removed lesions have a free margin or not.	At V2 day of Endoscopic Mucosal Reseaction (Day 1)
Secondary	Recurrent or residual neoplasia confirmed by repeat standard endoscopy and biopsy (if applicable) at the follow up visit		Day 60 follow up visit